Clinical trials: Glioma, High Grade
Glioblastoma
Exercise in Patients With Glioblastoma
Patients with newly-diagnosed GBM will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later.
- Trial name
- NCT03390569
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Brain and Central Nervous System Tumors
Procarbazine in Treating Patients With Recurrent Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have…
- Trial name
- NCT00004004
- Testing
- procarbazine hydrochloride
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Glioma
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia).
- Trial name
- NCT04309552
- Testing
- 18F-FMISO PET, 18F-FLT PET
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Weill Medical College of Cornell University
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
A Study of NST-628 in Recurrent Grade 4 Glioma
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression…
- Trial name
- NCT07784985
- Testing
- NST-628
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nader Sanai
Neoadjuvant Therapy, Carilizumab
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor.
- Conditions
- Neoadjuvant Therapy, Carilizumab, Apatinib, Recurrent High-Grade Glioma
- Trial name
- NCT04588987
- Testing
- PD-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Brain Glioma
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which…
- Trial name
- NCT06747728
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or…
- Trial name
- NCT00003241
- Testing
- phenylacetate
- Where
- 6 sites in United States
- Sponsor
- Texas Children's Cancer Center
Neoplasms
Continued Treatment for Participants Enrolled in Studies of BXQ-350
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the…
- Trial name
- ETERNITI (NCT04404569)
- Testing
- BXQ-350
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors, Thromboembolism
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas.
- Trial name
- NCT00253669
- Testing
- laboratory biomarker analysis, physiologic testing, management of therapy complications
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
FMISO-PET in Brain Tumors and SCS Effect
The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients.
- Trial name
- FMISOPETSCS (NCT01868906)
- Testing
- 18F-FMISO, PET without SCS, SCS
- Where
- 2 sites in Spain
- Volunteers
- 6 people
- Sponsor
- Bernardino Clavo, MD, PhD
Glioma, Malignant, High Grade Glioma
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
The primary goal of this Phase 1 study is to determine if a new investigational drug, OS2966, when delivered directly to the brain of adult participants with recurrent/progressive high-grade glioma (HGG) is safe and well…
- Conditions
- Glioma, Malignant, High Grade Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT04608812
- Testing
- OS2966, Gadoteridol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OncoSynergy, Inc.
Glioma, Glioma of Brain
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel…
- Conditions
- Glioma, Glioma of Brain, Cancer, Pediatric Cancer
- Trial name
- PNOC008 (NCT03739372)
- Testing
- Specialized tumor board recommendation
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
High-grade Glioma, Astrocytoma
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
18F-Fluorothymidine is a recently developed PET tracer to image tumor cell proliferation. Very few data report an interest of using such a tracer for cerebral malignant tumor management.
- Conditions
- High-grade Glioma, Astrocytoma, Glioblastoma
- Trial name
- GLIO-TEP (NCT00624728)
- Testing
- 18F Fluorothymidine PET CT
- Where
- 2 sites in France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Bordeaux
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
Childhood aggressive gliomas are rare brain tumors with very poor prognosis. Due to the tumor's location and infiltrative nature, surgical removal is not always possible, and even when resection is performed and combined with…
- Trial name
- ADDICT-pedGLIO (NCT04911621)
- Testing
- Dendritic cell vaccination + temozolomide-based chemoradiation, Dendritic cell vaccination +- conventional next-line treatment
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Neurofibromatosis 1 (NF1)
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a…
- Trial name
- NF118 (NCT07521657)
- Testing
- mirdametinib with radiation, mirdametinib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Alabama at Birmingham